Brought to you by 
BMS obtains rights to EntreMed's antiangiogenic compounds
06 Aug 1999
Executive Summary
Bristol-Myers Squibb licensed exclusive worldwide rights to antiangiogenic uses of EntreMed's thalidomide (in Phase II for cancers, macular degeneration), thalidomide analogs, and the Angiostatin protein in a 5-yr. collaboration worth up to $76mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS obtains rights to EntreMed's antiangiogenic compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice